| Field | Specification |
|---|---|
| Target | |
| Alternative names | Fumarate hydratase, mitochondrial; Fumarase; 4.2.1.2; FH; |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | A synthetic peptide corresponding to a sequence at the N-terminus of human FH, which shares 100% and 97.8% amino acid (aa) sequence identity with mouse and rat FH, respectively. |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody targets fumarate hydratase, mitochondrial (gene FH) in human, mouse and rat samples and is validated for flow cytometry, ICC/IF, IHC and Western blot. The predicted molecular weight is 54.6 kDa, and the supplier reports an observed band at about 49 kDa.
Fumarate hydratase (FH, fumarase) is a tricarboxylic acid (TCA) cycle enzyme in mitochondria that converts fumarate to L-malate; a cytosolic form also exists. Loss of FH causes fumarate to build up, and inherited FH mutations cause hereditary leiomyomatosis and renal cell cancer, so FH is studied in cancer metabolism and mitochondrial function.
| Target | Fumarate hydratase, mitochondrial (gene FH; UniProt P07954, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human, Mouse, Rat |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4; 0.05 mg NaN3 |
| Calculated MW | 54.6 kDa |
| Observed MW | 49 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.1–0.5 µg/mL |
|---|---|
| IHC (paraffin sections) | 0.5–1 µg/mL |
| IHC (frozen sections) | 0.5–1 µg/mL |
| Immunocytochemistry / Immunofluorescence | 2 µg/mL |
| Flow cytometry (fixed cells) | 1–3 µg/1×106 cells |
Samples with a confirmed band (WB): rat lymphaden tissue, rat small intestine tissue, rat gaster tissue, mouse kidney tissue, mouse testis tissue, mouse gaster tissue, human K562 cells, human U937 cells, human colon cancer tissue, human lung cancer tissue, human placenta tissue, mouse small intestine tissue, human mammary cancer tissue.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 50 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL, HRP-conjugated secondary antibody at 1:10000, ECL detection.
Samples with confirmed staining (ICC/IF): PC-3 cells.
Samples with a confirmed signal (flow cytometry): A431 cells, PC-3 cells.
Conditions in the example images (IHC): heat-mediated antigen retrieval in citrate buffer (pH 6).
Immunogen
Synthetic peptide from the N-terminal region of human FH. Sequence identity with the mouse and rat orthologs: 100% and 97.8%, respectively.
Reactivity Notes
The supplier lists reactivity with human, mouse and rat. Tissue expression noted by UniProt (human): Expressed in red blood cells. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
